NMRA
Neumora Therapeutics, Inc.
0.6918$
+2.1%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Cash Flow
Neumora Therapeutics, Inc. (NMRA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -206 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -27 | -27 | -75 | -115 | -163 | -183 | -206 | |
| 0.1 | 0.1 | 0.5 | 0.6 | 0.7 | 0.6 | 0.2 | |
| – | 1.7 | 4.3 | 8.3 | 17 | 40 | 30 | |
| 76 | 76 | 162 | 22 | – | – | – | |
| – | -3.1 | -1.0 | -6.9 | -8.9 | 23 | -0.4 | |
| 1.3 | 1.3 | 0.8 | 0.5 | 0.1 | 0.0 | 0.0 | |
| -11 | -11 | -0.8 | -168 | 64 | -71 | 169 | |
| – | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 | – | |
| 56 | 56 | 0.0 | – | – | 0.0 | 57 | |
| 230 | 230 | 294 | 116 | 232 | 22 | 77 | |
| 192 | 192 | 217 | -167 | 133 | -232 | 39 | |
| – | -28 | -76 | -115 | -163 | -183 | -206 |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.